jnj – q2 earnings

  • love point they are trimming portfolio and reinvesting proceeds for future rather than giving it all ack to shreholders
  • analyst focus is pharma
  • there were good points made about jnj credo and a bit of tranparency on drug pricing

more finacials this weekend

Leave a Reply

Your email address will not be published. Required fields are marked *